stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) Net income
Recursion Pharmaceuticals, Inc.'s net income for fiscal 2025 was −$644.8M, compared with −$463.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$475.7M. Over the past ten years it has ranged from −$644.8M (fiscal 2025) to $0.00 (fiscal 2017) — the current reading is the lowest in ten years. Net income has fallen for 6 consecutive fiscal years. Recursion Pharmaceuticals, Inc. ranks 585th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$644.8M | — |
| FY2024 | −$463.7M | — |
| FY2023 | −$328.1M | — |
| FY2022 | −$239.5M | — |
| FY2021 | −$186.5M | — |
| FY2020 | −$87.0M | — |
| FY2019 | −$61.9M | — |
| FY2019 | −$61.9M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$119.0M | — |
| Jun 2026 | −$131.0M | — |
| Mar 2026 | −$117.5M | — |
| Dec 2025 | −$108.1M | — |
| 24 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ADMA ADMA Biologics Inc compare | $182.4M |
| VCEL Vericel Corporation compare | $33.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| MBX MBX Biosciences, Inc. compare | −$104.3M |
| PHVS Pharvaris N.V. compare | −$193.1M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$204.9M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| RXRX Recursion Pharmaceuticals, Inc. | −$475.7M |
| BHVN Biohaven Ltd. compare | −$542.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on RXRX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement